Merck Sharp & Dohme Corp. v. Triveni Interchem Private Limited

Patents are the lifeblood of pharmaceutical innovation, but what happens when a competitor decides to ride on your R&D investment without permission? For Merck Sharp & Dohme Corp., the answer was swift and decisive: take the fight to court and secure an emergency injunction before irreparable damage is done. This case is a textbook example of how patent holders can use the legal system as a shield against unauthorized commercialization—and why courts take such claims seriously when the stakes involve public health and billion-dollar research investments.

Merck Sharp & Dohme Corp., a globally recognized pharmaceutical company, holds a valid patent for Sitagliptin, a well-known drug composition used in the treatment of type 2 diabetes. The plaintiff alleged that Triveni Interchem Private Limited, the defendant, was actively selling and advertising various compositions of Sitagliptin without obtaining any license or authorization from the patent holder. This unauthorized commercialization struck at the very heart of Merck's exclusive rights under its patent, prompting the company to file a suit seeking judicial intervention to stop the alleged infringement in its tracks.

The plaintiff, Merck, argued that it held a valid and subsisting patent for Sitagliptin, giving it the exclusive right to manufacture, sell, and license the drug composition. The defendant, Triveni Interchem, was allegedly infringing this exclusive right by selling and advertising Sitagliptin compositions without any license from Merck. The core legal friction centered on whether the plaintiff had made out a prima facie case of patent infringement and whether the continued unauthorized sale would cause irreparable loss that could not be compensated through monetary damages alone. The plaintiff contended that allowing the defendant to continue selling the patented composition would erode its market exclusivity, undermine its patent rights, and cause harm that extended beyond mere financial loss.

The court ruled in favor of the plaintiff, granting an ex-parte ad interim injunction under Order XXXIX Rules 1 and 2 of the Code of Civil Procedure (CPC). The court reasoned that the plaintiff had established a prima facie case of patent infringement and demonstrated that it would suffer irreparable loss if the defendant were allowed to continue its alleged unauthorized activities during the pendency of the suit. The interim order effectively restrained Triveni Interchem from selling or advertising Sitagliptin compositions without authorization from Merck, pending further hearing and final adjudication of the matter.

For founders and IP professionals, this case delivers a clear and actionable lesson: when you hold a valid patent and discover a competitor exploiting your invention without a license, move quickly. The law provides powerful interim remedies—specifically, ex-parte ad interim injunctions under Order XXXIX Rules 1 and 2 of the CPC—that can halt infringement before it causes lasting damage. The key is to demonstrate two things: a prima facie case of infringement and the likelihood of irreparable loss. In pharmaceutical and high-stakes IP matters especially, courts recognize that patent exclusivity is not just about revenue—it's about preserving the value of innovation. Don't wait for the damage to pile up; secure your rights at the earliest opportunity.